Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on June 17, 2009
JNCI Journal of the National Cancer Institute 2009 101(14):1028-1029; doi:10.1093/jnci/djp145
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
101/14/1028    most recent
djp145v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Thomssen, C.
Right arrow Articles by Vetter, M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thomssen, C.
Right arrow Articles by Vetter, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press.

CORRESPONDENCE

Feasibility of Measuring the Prognostic Factors uPA and PAI-1 in Core Needle Biopsy Breast Cancer Specimens

Christoph Thomssen, Nadia Harbeck, Juergen Dittmer, Shanti R. Abraha-Spaeth, Nancy Papendick, Angelo Paradiso, Bjoern Lisboa, Fritz Jaenicke, Manfred Schmitt, Martina Vetter

Affiliations of authors: Department of Gynaecology, Martin-Luther University Halle-Wittenberg, Halle (Saale), Germany (CT, JD, NP, MV); Department of Obstetrics and Gynaecology, University of Cologne, Cologne, Germany (NH); Department of Gynaecology, University of Hamburg, Hamburg, Germany (SRA-S, BL, FJ); Clinical Experimental Oncology Laboratory, National Cancer Institute, Bari, Italy (AP); Department of Obstetrics and Gynaecology, Technical University Munich, Munich, Germany (MS)

Correspondence to: Christoph Thomssen, MD, Department of Gynaecology, Martin-Luther University Halle-Wittenberg, Ernst Grube Str 40, 06120 Halle (Saale), Germany (e-mail: christoph.thomssen@medizin.uni-halle.de).

The first 10% of the full text of this article appears below.

Tumor invasion factors urokinase-type plasminogen activator (uPA) and its inhibitor plasminogen activator inhibitor 1 (PAI-1) are American Society of Clinical Oncology (ASCO)–recommended cancer biomarkers for assessing whether node-negative breast cancer patients can forgo adjuvant chemotherapy (1). Numerous retrospective and prospective analyses (2,3), a multicenter prospective clinical trial (4), and a meta-analysis (5) . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?